Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

Archives of General Psychiatry

Volumn 53, Issue 8, 1996, Pages 689-694

  Wiborg, Ida M ^a,b   Dahl, Alv A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Gaustad Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; MALE; PANIC; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029737480     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830080041008     Document Type: Article

References (47)

1. Klein DP, German JM. A model of panic and agoraphobia development. Acta Psychiatr Scand Suppl. 1987;335:87-95.
2. Sheehan DV. Tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics. 1986;27(suppl 11):10-16.
3. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books Inc; 1986.
4. Ballenger JC. Overview of the pharmacotherapy of panic disorder. In: Wolfe BE, Maser JD, eds. Treatment of Panic Disorder: A Consensus Development Conference. Washington, DC: American Psychiatric Press; 1994:59-72.
5. Ballenger JC. Efficacy of benzodiazepines in panic disorder and agoraphobia. J Psychiatr Res. 1990;24(suppl 2):15-25.
6. Sheehan DV. Benzodiazepines in panic disorder and agoraphobia. J Affect Disord. 1987:13:169-181.
7. Noyes R, DuPont RL, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, II: patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988:45:423-428.
8. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Davies SR, Goetz D, Klein DF. Alprazolam in the treatment of panic disorder. J Clin Psychopharmacol. 1986:6:13-20.
9. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol. 1994;14:111-118.
10. Zitrin CM, Klein DF, Woerner MG. Ross DC. Treatment of phobias, I: comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry. 1983;40: 125-138. :
11. Noyes R, Garvey MJ, Cook BL. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord. 1989;16:249-257.
12. Noyes R, Garvey MJ, Cook EL, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry. 1991; 148:517-523.
13. Shear MK, Maser JD. Standard assessment for panic disorder research. Arch Gen Psychiatry. 1994:51:346-354.
14. Mavissakalian M, Michelson L, Dealy RS. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry. 1983;143:348-355.
15. Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC. Combined pharmacological and bebavior treatment for agoraphobia. Behav Res Ther. 1985;23:325-335.
16. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliot PT, Kirby M, McNamee G, Sengun S, Wickwire K. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry. 1993;162:776-787.
17. Telch MJ, Lucas RA. Combined pharmacological and psychological treatment of panic disorder: current status and future directions. In: Wolfe BE, Maser JD, eds. Treatment of Panic Disorder: A Consensus Development Conference. Washington, DC: American Psychiatric Press; 1994:177-197.
18. Cohen SO, Monteiro W, Marks IM. Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry. 1984:144:276-281.
19. Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry. 1986:142:1032-1036.
20. Faravelli C. Life events preceding the onset of panic disorder. J Affect Disord. 1985:9:103-105.
21. Faravelli C, Pallanti S. Recent life events and panic disorder. Am J Psychiatry. 1989:146:622-626.
22. Roy-Byrne PP, Geraci M, Uhde TW. Life events and course of illness in patients with panic disorder. Am J Psychiatry. 1986:143:1033-1035.
23. Roy-Byrne PP, Geraci M, Uhde TW. Life events and the onset of panic disorder. Am J Psychiatry. 1986:143:1424-1427.
24. Roy-Byrne PP, Geraci M. Uhde TW. Life events obtained via interview: the effect of time of recall on data obtained in controls and patients with panic disorder. J Affect Disord. 1987:12:57-62.
25. Roy-Byrne PP, Uhde TW. Exogenous factors in panic disorder: clinical and research implications. J Clin Psychiatry. 1988;49:56-61.
26. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992:12:251-261.
27. Spitzer RL, Williams JBW. Revised diagnostic criteria and a new structured interview for diagnosing anxiety disorder. J Psychiatr Res. 1988;22:55-86.
28. Hyler SE, Rieder RO. PDU-R: Personality Diagnostic Questionnaire-Revised. New York, NY; New York State Psychiatric Institute: 1987.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
30. Davanloo H, ed. Basic Principles and Techniques In Short-Term Dynamic Psychotherapy. New York, NY: Spectrum; 1978.
31. Malan D. The Frontier of Brief Psychotherapy. New York, NY: Plenum Medical Books; 1976.
32. Malan D. The Frontier of Brief Psychotherapy: An Example of the Convergence of Research and Clinical Practice. New York, NY: Plenum Press; 1976.
33. Malan D. Individual Psychotherapy and the Science of Psychodynamics. London, England: Butterworth; 1979.
34. Strupp HH, Binder JL. Psychotherapy in a New Key: A Guide to Time-Limited Dynamic Psychotherapy. New York, NY: Basic Books Inc Publishers; 1984.
35. Derogatis LR. SCL-90: Administration Scoring and Procedures Manual-1 For the (Revised) Version. Baltimore, Md: Clinical Psychometrics Research Unit, John Hopkins University School of Medicine; 1977.
36. Spielberger C, Gorsuch A, Lushene R. The State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologist Press; 1970.
37. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976:33:766-771.
38. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976. Publication 76-338.
39. Hamilton M. The assessment of anxiety by rating. BrJMed Psychol. 1959; 32:50-55.
40. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books; 1986.
41. Panic Disorder: Patient's Status. Kalamazoo, Mich; The Upjohn Co: 1990. Reference 94-1557-41 01/90. Self-report questionnaire.
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960:23:56-62.
43. Panic Disorder: Medical Events Checklist. Kalamazoo, Mich; The Upjohn Co: 1990. Reference 94-1557-37 01/90. Interview-based questionnaire.
44. Hamre P, Dahl AA, Malt U. Public attitudes to the quality of psychiatric treatment, psychiatric patients, and the prevalence of mental disorder. Nord PsychiatrJ. 1994:48:275-281.
45. Ursano RJ, Sonnenberg SM, Lazar SG. Psychodynamic Psychotherapy. Washington, DC: American Psychiatric Press; 1991;102.
46. Clark DB, Taylor CB, Roth WT, Hayward C, Ehlers A, Margraf J, Agras WS. Surreptitious drug use by patients in a panic disorder study. Am J Psychiatry. 1991:36:130-138.
47. Millrod B, Shear MK. Psychodynamic treatment of panic: three case histories. Hosp Community Psychiatry. 1991;42:311-312.